CI Global Health Sciences Corporate Class

Series F CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4924) merged into (NL 224)
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
CAD Total net assets ($CAD)
As at 2024-03-28
$147.1 million
NAVPS
As at 2024-05-17
$39.6554
MER (%)
As at 2023-09-30
1.24
Management fee (%) 0.90
Asset class Sector Equity
Currency CAD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.6275

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 224
A ISC 201
DSC SO* 701
LL SO 1701
E 16005
EF 15005
I 886
O 18005
P 90024
*No new purchases directly into switch only funds.

Performance2 As at 2024-04-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
6.83% -2.48% 4.11% 10.69% 7.76% 2.41% 5.82% 5.20% 7.27%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.6275
2021-03-26 0.2155
2020-12-18 0.3483
2020-09-25 0.3458
2020-06-26 0.2577
Payable date Total
2020-03-20 0.6324
2019-12-13 0.3619
2019-09-27 0.4055
2019-06-21 0.3808
2019-03-22 0.6081

CI PREFERRED PRICING4

Investment amount Combined fee reduction
$100,000 - $500,000 0.03%
$500,000 - $1,000,000 0.06%
$1,000,000 - $2,500,000 0.12%
$2,500,000 - $5,000,000 0.20%
$5,000,000 and above 0.32%

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series F CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4924) merged into (NL 224)
 
Portfolio allocations5 As at 2024-04-30
Asset allocation (%)
  • US Equity 76.24
  • International Equity 21.60
  • Cash and Equivalents 2.16
Sector allocation (%)
  • Healthcare 94.36
  • Exchange Traded Fund 2.49
  • Cash and Cash Equivalent 2.16
  • Consumer Services 0.99
Geographic allocation(%)
  • United States 78.28
  • United Kingdom 9.57
  • Denmark 7.60
  • Germany 3.03
  • Switzerland 1.45
  • Canada 0.07
Top holdings
Sector (%)
1. Eli Lilly and Co Drugs 10.37%
2. UnitedHealth Group Inc Healthcare Services 9.45%
3. Novo Nordisk A/S Cl B Drugs 7.60%
4. Merck & Co Inc Drugs 6.62%
5. AstraZeneca PLC Drugs 6.35%
6. Thermo Fisher Scientific Inc Healthcare Equipment 4.97%
7. Anthem Inc Healthcare Services 4.87%
8. AbbVie Inc Drugs 4.26%
9. Zoetis Inc Cl A Drugs 4.25%
10. Cigna Corp Healthcare Services 4.06%
11. Usd Cash Sweep Cash and Cash Equivalent 3.30%
12. Gsk Plc Drugs 3.20%
13. Boston Scientific Corp Healthcare Equipment 3.12%
14. Siemens Healthineers AG Healthcare Equipment 3.03%
15. Stryker Corp Healthcare Equipment 3.02%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.